<p>Scilex（納斯達克代碼：SCLX - 獲取免費報告）於週五發佈了季度財報。該公司報告每股收益（EPS）為（$22.17），低於市場共識預期的（$0.41），差距為（$21.76），據 Zacks 報道。</p>
<h2>Scilex 價格表現</h2>
<ul>
<li>Datavault AI 的 314% 上漲：巨大的潛力還是華爾街的幻影？</li>
</ul>
<p>週五中午交易時，SCLX 的股價下跌了$0.18，跌至$17.69。該公司的股票交易量為 61,732 股，而其平均交易量為 146,317 股。該公司的 50 日移動平均價格為$19.97，200 日移動平均價格為$13.12。Scilex 的 52 周低點為$3.60，52 周高點為$34.27。該股票的市值為 1.3427 億美元，市盈率為-1.11，貝塔值為 1.34。</p>
<h2>機構資金流入和流出</h2>
<p>幾家機構投資者最近調整了對該股票的持有。高盛集團在第一季度將其在 Scilex 的持股增加了 31.2%。高盛集團現在擁有 136,352 股該公司的股票，價值$34,000，此前在上個季度增持了 32,449 股。挪威銀行在第二季度收購了 Scilex 的新股份，價值$80,000。最後，法國巴黎銀行金融市場在第三季度將其在 Scilex 的持股增加了 189.6%。法國巴黎銀行金融市場現在擁有 7,430 股該公司的股票，價值$146,000，此前在上個季度增持了 4,864 股。機構投資者持有該公司 69.67% 的股份。</p>
<h2>分析師評級調整</h2>
<ul>
<li>Datavault AI：由大額資金支持的新 AI 競爭者</li>
</ul>
<p>另外，Weiss Ratings 在 10 月 8 日的研究報告中重申了對 Scilex 的 “賣出（d-）” 評級。兩位分析師對該股票給予了持有評級，一位分析師給予了賣出評級。根據 MarketBeat 的數據，該公司的平均評級為 “減持”，平均目標價格為$630.00。</p>
<p><strong>查看我們最新的 SCLX 股票分析</strong></p>
<h2>關於 Scilex</h2>
<p>（獲取免費報告）</p>
<p>Scilex 控股公司專注於收購、開發和商業化非阿片類疼痛管理產品，以治療急性和慢性疼痛。其商業產品包括 ZTlido（利多卡因外用系統）1.8%（ZTlido），一種用於緩解與帶狀皰疹後神經痛（PHN）相關的神經性疼痛的處方利多卡因外用產品；ELXYB，一種用於急性治療成人偏頭痛（有或沒有先兆）的即用口服溶液；以及 GLOPERBA，一種用於預防成人痛風發作的液體口服版本的抗痛風藥物秋水仙鹼。</p>
<h2>精選文章</h2>
<ul>
<li>我們更看好的五隻股票比 Scilex 更好</li>
<li>如何計算股票利潤</li>
<li>這三家被低估的科技巨頭準備反彈嗎？</li>
<li>百分比漲幅告訴投資者什麼，以及為什麼它們並不能告訴全部故事</li>
<li>如果你等着抄底，美光科技可能會讓你錯過</li>
<li>現在買入 P&amp;G，在它創下新高之前</li>
<li>三隻悄然推動 AI 和科技革命的股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0NMWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0NMWA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Scilex 嗎？</h2>
<p>在考慮 Scilex 之前，你會想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議現在購買，以便在更廣泛的市場注意到之前……而 Scilex 並不在名單上。</p>
<p>雖然 Scilex 目前在分析師中被評為減持，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

SCLX

<p>Scilex（納斯達克代碼：SCLX）報告的季度每股收益（EPS）為（$22.17），顯著低於市場共識預期的（$0.41），差距達到$21.76。該公司的股票交易價格下跌至$17.69，市值為 1.3427 億美元。機構投資者持有該公司 69.67% 的股份。分析師對 Scilex 給予了 “減持” 評級，目標股價為$630.00。Scilex 專注於非阿片類疼痛管理產品，包括 ZTlido、ELYXYB 和 GLOPERBA</p>

<p>Scilex (NASDAQ:SCLX - Get Free Report) posted its quarterly earnings data on Friday. The company reported ($22.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($21.76), Zacks reports.</p>
<div class="lb-trans"><p>Scilex（納斯達克代碼：SCLX - 獲取免費報告）於週五發佈了季度財報。該公司報告每股收益（EPS）為（$22.17），低於市場共識預期的（$0.41），差距為（$21.76），據 Zacks 報道。</p>
</div><h2>Scilex Price Performance</h2>
<div class="lb-trans"><h2>Scilex 價格表現</h2>
</div><ul>
<li>Datavault AI's 314% Upside: Huge Potential or Wall Street Mirage?</li>
</ul>
<div class="lb-trans"><ul>
<li>Datavault AI 的 314% 上漲：巨大的潛力還是華爾街的幻影？</li>
</ul>
</div><p>Shares of SCLX traded down $0.18 during mid-day trading on Friday, hitting $17.69. The company's stock had a trading volume of 61,732 shares, compared to its average volume of 146,317. The firm has a 50-day moving average price of $19.97 and a 200 day moving average price of $13.12. Scilex has a fifty-two week low of $3.60 and a fifty-two week high of $34.27. The stock has a market capitalization of $134.27 million, a price-to-earnings ratio of -1.11 and a beta of 1.34.</p>
<div class="lb-trans"><p>週五中午交易時，SCLX 的股價下跌了$0.18，跌至$17.69。該公司的股票交易量為 61,732 股，而其平均交易量為 146,317 股。該公司的 50 日移動平均價格為$19.97，200 日移動平均價格為$13.12。Scilex 的 52 周低點為$3.60，52 周高點為$34.27。該股票的市值為 1.3427 億美元，市盈率為-1.11，貝塔值為 1.34。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Several institutional investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. lifted its position in shares of Scilex by 31.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 136,352 shares of the company's stock valued at $34,000 after acquiring an additional 32,449 shares during the last quarter. Norges Bank acquired a new stake in shares of Scilex during the second quarter worth $80,000. Finally, BNP Paribas Financial Markets lifted its holdings in shares of Scilex by 189.6% during the third quarter. BNP Paribas Financial Markets now owns 7,430 shares of the company's stock valued at $146,000 after purchasing an additional 4,864 shares during the last quarter. Institutional investors own 69.67% of the company's stock.</p>
<div class="lb-trans"><p>幾家機構投資者最近調整了對該股票的持有。高盛集團在第一季度將其在 Scilex 的持股增加了 31.2%。高盛集團現在擁有 136,352 股該公司的股票，價值$34,000，此前在上個季度增持了 32,449 股。挪威銀行在第二季度收購了 Scilex 的新股份，價值$80,000。最後，法國巴黎銀行金融市場在第三季度將其在 Scilex 的持股增加了 189.6%。法國巴黎銀行金融市場現在擁有 7,430 股該公司的股票，價值$146,000，此前在上個季度增持了 4,864 股。機構投資者持有該公司 69.67% 的股份。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級調整</h2>
</div><ul>
<li>Datavault AI: The New AI Contender Backed by Big Funding</li>
</ul>
<div class="lb-trans"><ul>
<li>Datavault AI：由大額資金支持的新 AI 競爭者</li>
</ul>
</div><p>Separately, Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Scilex in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company has an average rating of &#34;Reduce&#34; and an average price target of $630.00.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 10 月 8 日的研究報告中重申了對 Scilex 的 “賣出（d-）” 評級。兩位分析師對該股票給予了持有評級，一位分析師給予了賣出評級。根據 MarketBeat 的數據，該公司的平均評級為 “減持”，平均目標價格為$630.00。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on SCLX</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 SCLX 股票分析</strong></p>
</div><h2>About Scilex</h2>
<div class="lb-trans"><h2>關於 Scilex</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.</p>
<div class="lb-trans"><p>Scilex 控股公司專注於收購、開發和商業化非阿片類疼痛管理產品，以治療急性和慢性疼痛。其商業產品包括 ZTlido（利多卡因外用系統）1.8%（ZTlido），一種用於緩解與帶狀皰疹後神經痛（PHN）相關的神經性疼痛的處方利多卡因外用產品；ELXYB，一種用於急性治療成人偏頭痛（有或沒有先兆）的即用口服溶液；以及 GLOPERBA，一種用於預防成人痛風發作的液體口服版本的抗痛風藥物秋水仙鹼。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Scilex</li>
<li>How to Calculate Stock Profit</li>
<li>Are These 3 Oversold Tech Giants Ready to Rebound?</li>
<li>What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story</li>
<li>If You Wait for the Dip, Micron Technology Could Leave You Behind</li>
<li>Buy P&amp;G Now, Before It Sets A New All-Time High</li>
<li>3 Stocks Quietly Powering the AI and Tech Revolution</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Scilex 更好</li>
<li>如何計算股票利潤</li>
<li>這三家被低估的科技巨頭準備反彈嗎？</li>
<li>百分比漲幅告訴投資者什麼，以及為什麼它們並不能告訴全部故事</li>
<li>如果你等着抄底，美光科技可能會讓你錯過</li>
<li>現在買入 P&amp;G，在它創下新高之前</li>
<li>三隻悄然推動 AI 和科技革命的股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0NMWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=SCLX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Scilex Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Scilex 嗎？</h2>
</div><p>Before you consider Scilex, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Scilex 之前，你會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Scilex wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議現在購買，以便在更廣泛的市場注意到之前……而 Scilex 並不在名單上。</p>
</div><p>While Scilex currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Scilex 目前在分析師中被評為減持，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Scilex（納斯達克代碼：SCLX）公佈了收益結果，每股收益比預期低 21.76 美元